慢性淋巴细胞白血病疗效评估和预后研究进展：第56届美国血液学会年会报道

Progress of response evaluation and prognosis in chronic lymphocytic leukemia： reports from the 56th American Society of Hematology annual meeting

慢性淋巴细胞白血病（CLL）是一种高度异质性的B细胞慢性淋巴增殖性疾病，常累及淋巴结、骨髓、肝脾等。第56届美国血液学会年会从发病机制、治疗、疗效和预后评估等多个方面对CLL进行全面报道。在疗效评估和预后方面，以微小残留病为代表的新型指标的出现进一步丰富和完善了现有CLL疗效评估和预后体系。文章主要就CLL疗效判定和预后因素研究进展进行总结。

Chronic lymphocytic leukemia （CLL） is an incurable B cell chronic lymphoproliferative disorder with a highly heterogeneous clinical course. The malignant B lymphocytes that have a mature appearance infiltrate in to lymph node, bone marrow, liver and spleen. The 56th American Society of Hematology （ASH） annual meeting explored multiple aspects including pathogenesis, treatment, response evaluation and prognosis of CLL. Clinical outcome of CLL patients can be predicted more accurately by a series of novel markers such as minimal residual disease. The progress of response evaluation and prognosis in CLL were focused in this review.